Industry Growth Insights published a new data on “Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market”. The research report is titled “Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market research by Types (Valsartan, Irbesartan, Candesartan Cilexetil, Eprosartan, Irbesartan, Telmisartan, losartan, Olmesartan Medoxomil, Allisartan isoproxil), By Applications (High Blood Pressure, Congestive Heart Failure, Left Ventricular Hypertrophy, Atherosclerosis, Other), By Players/Companies Pfizer, Novartis, Merck, AstraZeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical, Shenzhen Salubris Pharmaceuticals , Sun Pharmaceutical, Mylan, Alembic Pharmaceuticals, Lupin, Aurobindo Pharma, Amneal Pharmaceuticals, Boehringer Ingelheim”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report
By Type
Valsartan, Irbesartan, Candesartan Cilexetil, Eprosartan, Irbesartan, Telmisartan, losartan, Olmesartan Medoxomil, Allisartan isoproxil
By Application
High Blood Pressure, Congestive Heart Failure, Left Ventricular Hypertrophy, Atherosclerosis, Other
By Companies
Pfizer, Novartis, Merck, AstraZeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical, Shenzhen Salubris Pharmaceuticals , Sun Pharmaceutical, Mylan, Alembic Pharmaceuticals, Lupin, Aurobindo Pharma, Amneal Pharmaceuticals, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Report Segments:
The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market is segmented on the basis of:
Types
Valsartan, Irbesartan, Candesartan Cilexetil, Eprosartan, Irbesartan, Telmisartan, losartan, Olmesartan Medoxomil, Allisartan isoproxil
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
High Blood Pressure, Congestive Heart Failure, Left Ventricular Hypertrophy, Atherosclerosis, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Merck
- AstraZeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Teva Pharmaceutical
- Shenzhen Salubris Pharmaceuticals
- Sun Pharmaceutical
- Mylan
- Alembic Pharmaceuticals
- Lupin
- Aurobindo Pharma
- Amneal Pharmaceuticals
- Boehringer Ingelheim
Highlights of The Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Valsartan
- Irbesartan
- Candesartan Cilexetil
- Eprosartan
- Irbesartan
- Telmisartan
- losartan
- Olmesartan Medoxomil
- Allisartan isoproxil
- By Application:
- High Blood Pressure
- Congestive Heart Failure
- Left Ventricular Hypertrophy
- Atherosclerosis
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-peptide drugs of angiotensin II receptor antagonist are medications that block the action of angiotensin II. This can reduce blood pressure and improve heart function.
Some of the major companies in the non-peptide drugs of angiotensin ii receptor antagonist market are Pfizer, Novartis, Merck, AstraZeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical, Shenzhen Salubris Pharmaceuticals , Sun Pharmaceutical, Mylan, Alembic Pharmaceuticals, Lupin, Aurobindo Pharma, Amneal Pharmaceuticals, Boehringer Ingelheim.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size & Forecast, 2018-2028
4.5.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Y-o-Y Growth
4.5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Absolute $ Opportunity
Chapter 5 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
5.2.1 Valsartan
5.2.2 Irbesartan
5.2.3 Candesartan Cilexetil
5.2.4 Eprosartan
5.2.5 Irbesartan
5.2.6 Telmisartan
5.2.7 losartan
5.2.8 Olmesartan Medoxomil
5.2.9 Allisartan isoproxil
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
6.2.1 High Blood Pressure
6.2.2 Congestive Heart Failure
6.2.3 Left Ventricular Hypertrophy
6.2.4 Atherosclerosis
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Analysis and Forecast
9.1 Introduction
9.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
9.6.1 Valsartan
9.6.2 Irbesartan
9.6.3 Candesartan Cilexetil
9.6.4 Eprosartan
9.6.5 Irbesartan
9.6.6 Telmisartan
9.6.7 losartan
9.6.8 Olmesartan Medoxomil
9.6.9 Allisartan isoproxil
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
9.10.1 High Blood Pressure
9.10.2 Congestive Heart Failure
9.10.3 Left Ventricular Hypertrophy
9.10.4 Atherosclerosis
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Analysis and Forecast
10.1 Introduction
10.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
10.6.1 Valsartan
10.6.2 Irbesartan
10.6.3 Candesartan Cilexetil
10.6.4 Eprosartan
10.6.5 Irbesartan
10.6.6 Telmisartan
10.6.7 losartan
10.6.8 Olmesartan Medoxomil
10.6.9 Allisartan isoproxil
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
10.10.1 High Blood Pressure
10.10.2 Congestive Heart Failure
10.10.3 Left Ventricular Hypertrophy
10.10.4 Atherosclerosis
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
11.6.1 Valsartan
11.6.2 Irbesartan
11.6.3 Candesartan Cilexetil
11.6.4 Eprosartan
11.6.5 Irbesartan
11.6.6 Telmisartan
11.6.7 losartan
11.6.8 Olmesartan Medoxomil
11.6.9 Allisartan isoproxil
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
11.10.1 High Blood Pressure
11.10.2 Congestive Heart Failure
11.10.3 Left Ventricular Hypertrophy
11.10.4 Atherosclerosis
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Analysis and Forecast
12.1 Introduction
12.2 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
12.6.1 Valsartan
12.6.2 Irbesartan
12.6.3 Candesartan Cilexetil
12.6.4 Eprosartan
12.6.5 Irbesartan
12.6.6 Telmisartan
12.6.7 losartan
12.6.8 Olmesartan Medoxomil
12.6.9 Allisartan isoproxil
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
12.10.1 High Blood Pressure
12.10.2 Congestive Heart Failure
12.10.3 Left Ventricular Hypertrophy
12.10.4 Atherosclerosis
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Type
13.6.1 Valsartan
13.6.2 Irbesartan
13.6.3 Candesartan Cilexetil
13.6.4 Eprosartan
13.6.5 Irbesartan
13.6.6 Telmisartan
13.6.7 losartan
13.6.8 Olmesartan Medoxomil
13.6.9 Allisartan isoproxil
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast by Applications
13.10.1 High Blood Pressure
13.10.2 Congestive Heart Failure
13.10.3 Left Ventricular Hypertrophy
13.10.4 Atherosclerosis
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market: Competitive Dashboard
14.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Merck
14.3.4 AstraZeneca
14.3.5 Jhonson and Johnson
14.3.6 Eli Lilly
14.3.7 Sanofi
14.3.8 Bristol-Myers Squibb
14.3.9 Bayer
14.3.10 GSK
14.3.11 Teva Pharmaceutical
14.3.12 Shenzhen Salubris Pharmaceuticals
14.3.13 Sun Pharmaceutical
14.3.14 Mylan
14.3.15 Alembic Pharmaceuticals
14.3.16 Lupin
14.3.17 Aurobindo Pharma
14.3.18 Amneal Pharmaceuticals
14.3.19 Boehringer Ingelheim
